Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

Y0000193

Carteolol for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Carteolol monohydrochloride

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C16H24N2O3 · HCl
Número CAS:
51781-21-6
Peso molecular:
328.83
Código UNSPSC:
41116107
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

carteolol

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

temperatura de armazenamento

2-8°C

InChI

1S/C16H24N2O3.ClH/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13;/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20);1H

chave InChI

FYBXRCFPOTXTJF-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Carteolol for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

The possible treatment of migraine with carteolol hydrochloride.
M K Shapiro et al.
Headache, 39(2), 138-139 (2008-06-21)
Tetsuya Yamamoto
Nippon Ganka Gakkai zasshi, 111(6), 463-472 (2007-07-03)
To compare the ocular hypotensive activity and safety profile of long-acting 1% carteolol hydrochloride eye drops (long-acting formulation) to those of 1% carteolol hydrochloride eye drops(currently prescribed drug) for reduction of intraocular pressure. Patients with primary open-angle glaucoma or ocular
Tetsuya Sugiyama et al.
Acta ophthalmologica, 87(7), 797-800 (2008-12-05)
To assess the effects of combined therapy with latanoprost and beta blockers on optic nerve head (ONH) blood flow in normal-tension glaucoma (NTG) patients. Intraocular pressure (IOP), ONH blood flow (laser speckle flowgraphy) and blood pressure were measured in 15
Maura Floreani et al.
European journal of pharmacology, 590(1-3), 269-275 (2008-06-24)
This in vitro study was designed to investigate whether carteolol, a non-conventional partial agonists of beta(1)-adrenoceptors, relaxes phenylephrine-constricted rat aorta through activation of the low-affinity state of beta(1)-adrenoceptors or antagonist effect at alpha(1)-adrenoceptors. Carteolol-induced complete concentration-dependent relaxation of phenylephrine-contracted aorta
Grégory Spataro et al.
European journal of medicinal chemistry, 45(1), 326-334 (2009-11-06)
New series of phosphorus-containing dendrimers, having one quaternary ammonium salt as core and carboxylic acid terminal groups have been synthesized from generation 0 (3 carboxylic acid terminal groups) to generation 2 (12 carboxylic acid terminal groups). These dendrimers react with
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica